GeneBioTech Co. ,Ltd (KOSDAQ:086060)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,030.00
+260.00 (5.45%)
At close: Feb 13, 2026

GeneBioTech Co. ,Ltd Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
10,50410,2798,7517,4307,4308,794
Short-Term Investments
11,63513,12513,2658,66010,36018,593
Cash & Short-Term Investments
22,13923,40422,01616,09017,79027,387
Cash Growth
-8.94%6.31%36.83%-9.56%-35.04%9.38%
Accounts Receivable
15,11713,36411,58814,09010,2256,655
Other Receivables
793.61356.36180.69183.8274.8580.37
Receivables
16,24014,05311,81814,30210,3716,899
Inventory
13,89617,04114,80215,45213,67610,441
Prepaid Expenses
17.2427.2724.1625.6641.0544.35
Other Current Assets
2,9021,310621.38399.76298.05698.85
Total Current Assets
55,19455,83649,28146,26942,17545,470
Property, Plant & Equipment
16,64313,92414,15914,61514,90012,910
Long-Term Investments
2,270639.43718.86484.19763.61,241
Goodwill
---589.54589.54589.54
Other Intangible Assets
598.76648.82632.02398.29199.07198.94
Long-Term Deferred Tax Assets
50.1366.76205.29495.41870.49521.64
Other Long-Term Assets
268.65436.81513666.71294.23376.97
Total Assets
75,43171,98866,01764,04160,36862,085
Accounts Payable
4,3743,3663,5403,9014,7521,671
Accrued Expenses
1,3791,077970.5649.23515.74532.03
Short-Term Debt
7,09410,8517,7049,4868,0424,352
Current Portion of Long-Term Debt
1,5092,3591,5341,159--
Current Portion of Leases
82.2295.17132.9242.29112.3969.15
Current Income Taxes Payable
336.33278.37284.2714.46-237.89
Current Unearned Revenue
-----1.96
Other Current Liabilities
853.41337.78347.33667.94716.5815.97
Total Current Liabilities
15,62818,36414,51315,92014,1397,680
Long-Term Debt
5,3562,4662,9952,3292,1131,113
Long-Term Leases
84.12113.47135.0812.3533.5768.66
Pension & Post-Retirement Benefits
262.15----0
Other Long-Term Liabilities
74.4672.0768.5453.021372,795
Total Liabilities
21,40521,01617,71218,31516,42311,657
Common Stock
4,3054,3054,3054,3054,3054,305
Additional Paid-In Capital
14,57614,57614,57614,57614,48914,835
Retained Earnings
34,90031,80329,05918,11616,19016,844
Comprehensive Income & Other
244.32288.42364.078,7298,9619,059
Total Common Equity
54,02650,97248,30545,72643,94545,043
Shareholders' Equity
54,02650,97248,30545,72643,94550,428
Total Liabilities & Equity
75,43171,98866,01764,04160,36862,085
Total Debt
14,12615,88512,50213,02910,3025,603
Net Cash (Debt)
8,0137,5199,5143,0617,48821,784
Net Cash Growth
-6.32%-20.97%210.80%-59.12%-65.62%182.38%
Net Cash Per Share
930.41873.231104.91355.50869.682529.89
Filing Date Shares Outstanding
8.618.618.618.618.618.61
Total Common Shares Outstanding
8.618.618.618.618.618.61
Working Capital
39,56637,47234,76830,34928,03737,791
Book Value Per Share
6274.335919.735609.935310.445103.625231.12
Tangible Book Value
53,42750,32347,67344,73843,15744,255
Tangible Book Value Per Share
6204.805844.375536.525195.725012.045139.55
Land
7,0117,0117,0615,4645,4644,115
Buildings
10,0843,7596,5336,4896,4714,101
Machinery
9,9791,9319,3429,2559,2229,140
Construction In Progress
-595.1341.651,6201,0071,935
Source: S&P Global Market Intelligence. Standard template. Financial Sources.